Label expansion for CIBINQO provides new systemic oral option for adolescents (12 to <18 years) with moderate-to-severe atopic dermatitis
This clearance allows the company to initiate a clinical trial for patients with an ileal pouch-anal anastomosis
The supplemental New Drug Application is based on results from the landmark EMPA-KIDNEY phase III trial
Swiftmelt 1515-I meets performance requirements and secures skin attachment
Advanz Pharma will leverage its specialty, hospital, and rare disease expertise and infrastructure to commercialize AT-007 in Europe for both Galactosemia and SORD Deficiency
If approved, the vaccine could help simplify the meningococcal vaccination schedule and provide the broadest serogroup coverage of any meningococcal vaccine
MindRank expects to initiate a Phase I safety study in the first quarter of 2023.
Proceeds from the transaction will be reinvested towards the growth, innovation and expansion of Healthium’s advanced surgery, orthopaedics, wound care and post-surgical care portfolio
Application includes data from key phase III trials, including the pivotal MOMENTUM trial, which met all primary and key secondary efficacy endpoints
Subscribe To Our Newsletter & Stay Updated
